Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB3 | P13945 | 1/20 | 0.39 |
| ▸ | BACE1 | P56817 | 5/20 | 0.34 |
| ▸ | CYP51A1 | Q16850 | 4/20 | 0.33 |
| ▸ | CXCR2 | P25025 | 2/20 | 0.32 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.32 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.31 |
| ▸ | HTR1A | P08908 | 2/20 | 0.31 |
| ▸ | HTR1D | P28221 | 2/20 | 0.31 |
| ▸ | HTR1B | P28222 | 2/20 | 0.31 |
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.30 |
| ▸ | RXRA | P19793 | 1/20 | 0.30 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4463452 | 1.00 | ADRB3 (0.39) | ADRB3BACE1CYP51A1CXCR2CXCR1 | |
| SCHEMBL4458820 | 0.88 | BACE1 (0.41) | ADRB3BACE1 | |
| SCHEMBL4458816 | 0.88 | BACE1 (0.41) | ADRB3BACE1 | |
| SCHEMBL4461518 | 0.86 | CYP51A1 (0.41) | ADRB3BACE1CYP51A1 | |
| SCHEMBL4461517 | 0.86 | CYP51A1 (0.41) | ADRB3BACE1CYP51A1 | |
| SCHEMBL27635152 | 0.86 | CYP51A1 (0.37) | ADRB3BACE1CYP51A1 | |
| SCHEMBL4472266 | 0.85 | ADRB3 (0.41) | ADRB3BACE1CXCR2CXCR1 | |
| SCHEMBL4472271 | 0.85 | ADRB3 (0.41) | ADRB3BACE1CXCR2CXCR1 | |
| SCHEMBL6802914 | 0.84 | ADRB3 (0.39) | ADRB3BACE1 | |
| SCHEMBL6802909 | 0.84 | ADRB3 (0.39) | ADRB3BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7629366-B2 | Aminoalcohol derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2009-12-08 | — | — | US | disclosed |
| US-20060100252-A1 | Aminoalcohol derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-11 | — | — | US | disclosed |
| US-7037938-B2 | Aminoalcohol derivatives | ASTELLAS PHARMA INC. (JP) | 2006-05-02 | — | — | US | disclosed |
| US-20040006143-A1 | For therapy of urinary incontinence | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100252-A1 | Aminoalcohol derivatives | H1-0, CHRM2, CHRM1 | ADRB3 130/4885BACE1 3315/4885CYP51A1 1727/4885 |
| US-20040006143-A1 | For therapy of urinary incontinence | H1-0, HRH2, H1-2 | ADRB3 568/4885BACE1 3808/4885CYP51A1 1390/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.